The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
Abstract
BACKGROUND: Nicotine establishes and maintains tobacco dependence. Individuals with genetically deficient CYP2A6 nicotine metabolism are at lower risk to become smokers and, if dependent, will smoke fewer cigarettes. Hepatic CYP2A6 accounts for nicotine's low systemic bioavailability, precluding oral nicotine replacement to treat dependence. OBJECTIVE: We sought to determine whether CYP2A6 inhibition via oral methoxsalen decreases nicotine clearance, increases nicotine bioavailability, and decreases smoking. METHODS: Two within-subject designs in healthy tobacco-dependent volunteers were conducted: a singleblind kinetic study (n = 17) of methoxsalen 30, 10, or 3.5 mg or placebo given with nicotine 4 mg orally to abstinent smokers; and a double-blind randomized crossover study (n = 11) of methoxsalen 30 mg or placebo crossed with nicotine 4 mg given orally or placebo before 60 minutes' abstinence and 90 minutes' free smoking. RESULTS: Placebo plus nicotine 4 mg orally increased the mean 3-hour plasma nicotine level by 4 ng/mL over residual baseline nicotine level, whereas methoxsalen 10 or 30 mg plus nicotine increased it by 9 ng/mL (P<.01), demonstrating in vivo inhibition of CYP2A6 nicotine metabolism. Methoxsalen 30 mg plus nicotine 4 mg given orally decreased breath carbon monoxide concentration at the end of free smoking by 47% (4.6 versus 8.7 ppm; P<.01) and cigarettes smoked by 24% (3.1 versus 4.1, P<.01) compared with placebo plus placebo. CONCLUSIONS: Methoxsalen inhibits nicotine first-pass metabolism of orally administered nicotine, and the combination directly reduces smoking in a laboratory setting. CYP2A6 inhibitors may have an important role in smoking cessation and tobacco exposure reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Nicotine delivery kinetics and abuse liability.
Henningfield, J. E., & Keenan, R. M. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.5.743 · Cited by 411
Cited by
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1
DEMPSEY, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.011 · Cited by 429
Schoedel, K. A., Hoffmann, E. B., Rao, Y., Sellers, E. M., & Tyndale, R. F. (2004) · Pharmacogenetics · doi:10.1097/00008571-200409000-00006 · Cited by 315
Self-citationHuman Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012724 · Cited by 308
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*
Malaiyandi, V., Sellers, E. M., & Tyndale, R. F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.011 · Cited by 267
Self-citation
Metadata
- Authors
- Sellers, E.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-07
- Volume
- 68
- Issue
- 1
- Pages
- 35-43
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W1987867942
- Cited by
- 179
- References
- 2
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.